Chédiak-Higashi syndrome: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} | |||
{{CMG}} '''Assosciate Editor(s)-In-Chief:''' [[User: Prashanthsaddala|Prashanth Saddala M.B.B.S]]; {{RT}} | |||
'''For patient information on this page, click [[Chédiak-Higashi syndrome (patient information)|here]]''' | |||
{{SK}} Oculocutaneous albinism with leukocyte defect; Beguez Cesar disease; Chediak-Steinbrinck-Higashi Syndrome; leukocytic anomaly albinism | |||
{{Infobox_Disease | | {{Infobox_Disease | | ||
Name = {{PAGENAME}} | | Name = {{PAGENAME}} | | ||
| Line 14: | Line 21: | ||
MeshID = D002609 | | MeshID = D002609 | | ||
}} | }} | ||
==Overview== | ==Overview== | ||
| Line 28: | Line 27: | ||
==Historical Perspective== | ==Historical Perspective== | ||
It is named for the [[Cuba]]n physician and serologist [[Alejandro Moisés Chédiak]] (1903-1993) and the [[Japan]]ese pediatrician [[Otokata Higashi]] (1902-1981).<ref>{{cite book |title=Neurocutaneous Disorders: Phakomatoses and Hamartoneoplastic Syndromes |chapter=Silver hair syndromes: Chediak–Higashi syndrome (CHS) and Griscelli syndromes (GS) |author=Saez-De-Ocariz M, Orozco-Covarrubias L, Duràn-McKinster C, Ruiz-Maldonado R |publisher=Springer |doi=10.1007/978-3-211-69500-5_19 |isbn=978-3-211-21396-4 |pages=407–26 |year=2008 |editor=Ruggieri M, Pascual-Castroviejo I, Di Rocco C, editors }}</ref> It is often spelled without the accent as Chediak–Higashi syndrome. | It is named for the [[Cuba]]n physician and serologist [[Alejandro Moisés Chédiak]] (1903-1993) and the [[Japan]]ese pediatrician [[Otokata Higashi]] (1902-1981).<ref>{{cite book |title=Neurocutaneous Disorders: Phakomatoses and Hamartoneoplastic Syndromes |chapter=Silver hair syndromes: Chediak–Higashi syndrome (CHS) and Griscelli syndromes (GS) |author=Saez-De-Ocariz M, Orozco-Covarrubias L, Duràn-McKinster C, Ruiz-Maldonado R |publisher=Springer |doi=10.1007/978-3-211-69500-5_19 |isbn=978-3-211-21396-4 |pages=407–26 |year=2008 |editor=Ruggieri M, Pascual-Castroviejo I, Di Rocco C, editors }}</ref> It is often spelled without the accent as Chediak–Higashi syndrome. | ||
==Classification== | |||
==Pathophysiology== | ==Pathophysiology== | ||
| Line 43: | Line 44: | ||
* Bleeding disorders | * Bleeding disorders | ||
* Periodontal disease of deciduous dentition | * Periodontal disease of deciduous dentition | ||
===Genetics=== | ===Genetics=== | ||
Chediak-Higashi syndrome is [[inherited]] in a [[autosomal recessive]] pattern. | Chediak-Higashi syndrome is [[inherited]] in a [[autosomal recessive]] pattern. | ||
| Line 52: | Line 52: | ||
role is unknown.<ref>{{ cite web |url=http://ghr.nlm.nih.gov/condition=chediakhigashisyndrome | | role is unknown.<ref>{{ cite web |url=http://ghr.nlm.nih.gov/condition=chediakhigashisyndrome | | ||
title=Chediak–Higashi syndrome | accessdate=2008-11-06 }}</ref> | title=Chediak–Higashi syndrome | accessdate=2008-11-06 }}</ref> | ||
==Differentiating {{PAGENAME}} from Other Diseases== | |||
==Epidemiology and Demographics== | |||
==Risk Factors== | |||
==Screening== | |||
==Natural History, Complications and Prognosis== | ==Natural History, Complications and Prognosis== | ||
===Natural History=== | |||
===Complications=== | ===Complications=== | ||
* Life threatening [[infections]] | * Life threatening [[infections]] | ||
| Line 69: | Line 79: | ||
==Diagnosis== | ==Diagnosis== | ||
===Diagnostic Criteria=== | |||
===History and Symptoms=== | ===History and Symptoms=== | ||
Patients with Chediak-Higashi syndrome usually present with thefollowing symptoms: | Patients with Chediak-Higashi syndrome usually present with thefollowing symptoms: | ||
| Line 124: | Line 136: | ||
There is no specific treatment for Chédiak–Higashi syndrome. Bone marrow transplants appear to have been successful in several patients. Infections are treated with antibiotics and abscesses are surgically drained when appropriate. Antiviral drugs such as [[acyclovir]] have been tried during the | There is no specific treatment for Chédiak–Higashi syndrome. Bone marrow transplants appear to have been successful in several patients. Infections are treated with antibiotics and abscesses are surgically drained when appropriate. Antiviral drugs such as [[acyclovir]] have been tried during the | ||
terminal phase of the disease. [[Cyclophosphamide]] and [[prednisone]] have been tried. [[Vitamin C]] therapy has improved immune function and clotting in some patients. | terminal phase of the disease. [[Cyclophosphamide]] and [[prednisone]] have been tried. [[Vitamin C]] therapy has improved immune function and clotting in some patients. | ||
===Medical therapy=== | |||
===Surgery=== | |||
===Prevention=== | ===Prevention=== | ||
| Line 134: | Line 149: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Pediatrics | [[Category:Pediatrics]] | ||
[[Category:Dermatology | [[Category:Dermatology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Endocrinology]] | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Latest revision as of 16:32, 22 July 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Assosciate Editor(s)-In-Chief: Prashanth Saddala M.B.B.S; Raviteja Guddeti, M.B.B.S. [2]
For patient information on this page, click here
Synonyms and keywords: Oculocutaneous albinism with leukocyte defect; Beguez Cesar disease; Chediak-Steinbrinck-Higashi Syndrome; leukocytic anomaly albinism
| Chédiak-Higashi syndrome | |
| ICD-10 | E70.3 (E70.340 ILDS) |
|---|---|
| ICD-9 | 288.2 |
| OMIM | 214500 |
| DiseasesDB | 2351 |
| MeSH | D002609 |
Overview
Chédiak-Higashi syndrome is a rare childhood autosomal recessive disorder that affects multiple systems of the body, and arises from a mutation in the lysosomal trafficking regulator gene, LYST. It arises from a microtubule polymerization defect which leads to a decrease in phagocytosis. The decrease in phagocytosis results in recurrent pyogenic infections, partial albinism, and peripheral neuropathy.
Historical Perspective
It is named for the Cuban physician and serologist Alejandro Moisés Chédiak (1903-1993) and the Japanese pediatrician Otokata Higashi (1902-1981).[1] It is often spelled without the accent as Chediak–Higashi syndrome.
Classification
Pathophysiology
Chediak-Higashi syndrome is a disease with impaired bacteriolysis due to failure of phagolysosome formation. As a result of disordered intracellular trafficking there is impaired lysosome degranulation with phagosomes, so phagocytosed bacteria are not destroyed by the lysosome's enzymes.
In addition, secretion of lytic secretory granules by cytotoxic T cells is also affected.
The disease is characterised by large lysosome vesicles in phagocytes (neutrophils), which thus have poor bactericidal function, leading to susceptibility to infections, abnormalities in nuclear structure of leukocytes, anaemia, and hepatomegaly.
Most children with Chédiak–Higashi syndrome ultimately reach a stage known as the accelerated phase — the lymphoma-like-syndrome. This severe phase of the disease is thought to be triggered by a viral infection (usually the Epstein-Barr virus, EBV). In the accelerated phase, defective white blood cells divide uncontrollably and invade many of the body's organs. The accelerated phase is associated with fever, episodes of abnormal bleeding, overwhelming infections, and organ failure. These medical problems are usually life-threatening in childhood.
Associated features:
- Abnormalities in melanocytes (albinism)
- Nerve defects
- Bleeding disorders
- Periodontal disease of deciduous dentition
Genetics
Chediak-Higashi syndrome is inherited in a autosomal recessive pattern.
Causes
Chédiak–Higashi syndrome is caused by mutations in the LYST gene. This gene provides instructions for making a protein known as the lysosomal trafficking regulator. Researchers believe that this protein plays a role in the transport (trafficking) of materials into structures called lysosomes. Lysosomes act as recycling centers within cells. They use digestive enzymes to break down toxic substances, digest bacteria that invade the cell, and recycle worn-out cell components. Although the lysosomal trafficking regulator protein is involved in the normal function of lysosomes, its exact role is unknown.[2]
Differentiating Chédiak-Higashi syndrome from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Natural History
Complications
- Life threatening infections
- Pyodermas and deep abscesses
- Neuropathy - begins in the teenage years
- Life threatening bleeding
- Loss of vision
- Renal failure
- Frequent infections especially with Epstein-Barr virus
- Lymphoma-like cancer
- Early death
Prognosis
Death often occurs in the first 10 years of life, from chronic infections or accelerated disease that results in lymphoma-like illness. However, some affected children have survived longer.
Diagnosis
Diagnostic Criteria
History and Symptoms
Patients with Chediak-Higashi syndrome usually present with thefollowing symptoms:
- Dizziness
- Weakness
- Photophobia
- Tremor
- Photosensitive skin
- Neuropathy
- Frequent infections - Staphylococcus aureus
- Numbness
- Seizures
- Unsteady walking (ataxia)
- Nosebleeds or easy bruising
- Intellectual disability (mental retardation)
Physical Examination
Skin
- Hypopigmentation skin (albinism) - partial
- Silvery hair
Eye
Abdomen
Neurologic
Laboratory Findings
- Complete blood count and differential count - reveal neutropenia, thrombocytopenia
- Hypergammaglobulinemia
- Bleeding time - prolonged
- Liver function tests - elevated bilirubin
- Peripheral blood smear - giant granules in neutrophils, eosinophils, and granulocytes are seen when examined using light microscopy.
- Bone marrow smear - peroxidase positive giant inclusion bodies in leukocyte precursor cells. The inclusion bodies contain lysosomal enzymes.
- Fluorescence cytometric analysis of leukocyte granules
Imaging
CT
- Brain and spinal cord atrophy
MRI
- Brain and spinal cord atrophy
EMG
- Delayed nerve conduction
EEG
- May reveal seizure activity
Treatment
There is no specific treatment for Chédiak–Higashi syndrome. Bone marrow transplants appear to have been successful in several patients. Infections are treated with antibiotics and abscesses are surgically drained when appropriate. Antiviral drugs such as acyclovir have been tried during the terminal phase of the disease. Cyclophosphamide and prednisone have been tried. Vitamin C therapy has improved immune function and clotting in some patients.
Medical therapy
Surgery
Prevention
Genetic counseling is recommended before becoming pregnant if you have a family history of Chediak-Higashi.
See also
- Griscelli syndrome (also known as "Chédiak-Higashi like syndrome")
References
- ↑ Saez-De-Ocariz M, Orozco-Covarrubias L, Duràn-McKinster C, Ruiz-Maldonado R (2008). "Silver hair syndromes: Chediak–Higashi syndrome (CHS) and Griscelli syndromes (GS)". In Ruggieri M, Pascual-Castroviejo I, Di Rocco C, editors. Neurocutaneous Disorders: Phakomatoses and Hamartoneoplastic Syndromes. Springer. pp. 407–26. doi:10.1007/978-3-211-69500-5_19. ISBN 978-3-211-21396-4.
- ↑ "Chediak–Higashi syndrome". Retrieved 2008-11-06.